A combined artificial intelligence–wet lab approach identifies a pivotal role of the NAD+–mitophagy axis on aging and neurodegeneration

by Clinical Neuropsychologist Online | Friday, August 21, 2026 | Dementia

Abstract INTRODUCTION Emerging evidence points to a role of nicotinamide mononucleotide (NAD+) depletion and compromised mitophagy in aging and neurodegenerative diseases. We hypothesize that age-dependent impairment of the NAD+–mitophagy axis contributes to brain...

Serum sodium, tonicity, and risk of dementia in cohort and healthcare populations

by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia

Abstract INTRODUCTION Identifying modifiable, accessible dementia risk factors is critical for prevention. Worldwide surveys indicate that about half of adults do not meet recommended fluid intake and may be chronically underhydrated. METHODS We examined associations...

Arachnoid granulation morphologies and β‐amyloid and tau pathology in older adults

by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia

Abstract INTRODUCTION Arachnoid granulations (AG) prominently enlarge with age, yet limited studies evaluate AG in neurodegeneration. Here, we investigate the associations of AG morphologies with Alzheimer’s disease (AD). METHODS Macroscopic AG properties were...

Optimized plasma p‐tau217 and p‐tau217/Aβ42 cutoffs enhance detection of pre‐clinical Alzheimer’s disease across diverse participants

by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia

Abstract INTRODUCTION Plasma p-tau217 and p-tau217/Aβ42 reliably identify non-Hispanic White individuals with symptomatic and pre-clinical AD. However, performance across ethnoracially diverse groups remains unknown. METHODS Cognitively normal Black, Hispanic, and...

Plasma proteomics of cerebrovascular disease, cognitive decline, and clinical outcomes

by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia

Abstract INTRODUCTION The plasma proteomic signatures underlying cerebrovascular disease (CeVD) remains poorly understood. METHODS A total of N = 2534 participants across two independent longitudinal Southeast-Asian cohorts were included. We profiled 1441 baseline...

Group‐level versus individualized approaches for capturing tau PET changes and clinical progression in Alzheimer’s disease

by Clinical Neuropsychologist Online | Thursday, August 20, 2026 | Dementia

Abstract INTRODUCTION Quantification approaches based on group-level regions of interest (ROIs) are widely used for evaluating tau positron emission tomography (PET) and clinical progression in Alzheimer’s disease (AD), but we hypothesize that personalized...